Mitophagy and Mitochondrial DNA Dynamics During Ramadan Dry Fasting vs 16:8 Time-Restricted Feeding

N/ANot Yet RecruitingNCT07638696

Bahcesehir Cyprus University120 enrolled

Overview

This study investigates how different types of fasting affect cell health, specifically focusing on how mitochondria (the energy-producing parts of cells) are cleared and renewed. While standard intermittent fasting allows water intake, Ramadan dry fasting involves total restriction of both food and fluids from dawn to sunset. Researchers want to see if the combined effects of fluid restriction and natural daily body rhythms during Ramadan trigger a stronger cellular cleanup process (called mitophagy) compared to standard 16:8 water-permitted fasting. The study will look at how these fasting habits change blood markers related to mitochondrial DNA and metabolic health across a 30-day period. This research will help determine if dry fasting offers distinct biological benefits for cellular renewal.

This is a prospective, single-centre, parallel-group, longitudinal observational cohort study conducted across Ramadan 2027. The study aims to evaluate the distinct molecular and metabolic trajectories of intermittent dry fasting compared to standard fluid-permitted time-restricted feeding (TRF). Participants will be allocated to one of two parallel groups based on their self-selected, established fasting practices: * Group A (Ramadan Dry Fasting): Observing complete fluid and nutrient deprivation from dawn (Fajr) to sunset (Maghrib) for 30 consecutive days. * Group B (16:8 TRF): Practicing a 16-hour daily fasting window with water/fluids permitted, observed concurrently during the same calendar period. Participants in both groups will be pairwise-matched based on age and BMI at screening. Blood samples will be collected from all participants at five distinct milestones: * T0: Pre-Ramadan baseline (Day -3) * T1: Acute induction phase (Day 7) * T2: Mitochondrial turnover phase (Day 14) * T3: Saturation plateau / primary endpoint (Day 30) * T4: Post-Ramadan recovery phase (Day 44) Peripheral blood mononuclear cells (PBMCs) and serum will be isolated from the collected blood. Laboratory analyses will measure mitochondrial DNA (mtDNA) copy number changes via qPCR, alongside a quantitative gene expression panel evaluating key regulators of mitophagy (such as PINK1 and Parkin), mitochondrial biogenesis, and general autophagy. Secondary evaluations include routine serum metabolic indicators, inflammatory markers, and dietary monitoring to evaluate the physiological pathways predicted by computational systems pharmacology.

Study Type

OBSERVATIONAL

Enrollment

Interventions

Ramadan Intermittent Dry Fasting (Sawm)BEHAVIORAL

Total fluid and nutrient restriction enforced daily from dawn (Fajr) to sunset (Maghrib) for 30 consecutive days. Food and fluid consumption are restricted to the nocturnal period

16:8 Time-Restricted Feeding (TRF)BEHAVIORAL

A 16-hour daily fasting window where calorie-containing foods and beverages are completely restricted. Fluid intake (such as water or uncaloried drinks) is permitted throughout the fasting period

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Common Criteria (Both Arms): * Age 18-50 years * BMI 18.5-30.0 kg/m²\[cite: 1\] * Non-smoker for at least 12 months\[cite: 1\] * No chronic disease requiring regular prescription medication\[cite: 1\] * Stable sleep-wake schedule (self-reported sleep midpoint deviation less than 90 minutes)\[cite: 1\] * Willing and able to attend all five study visits at the specified times\[cite: 1\] Arm A Specific (Ramadan Dry Fasting): \- Documented religious commitment and intention to complete all 30 days of Ramadan 2027 fasting\[cite: 1\] Arm B Specific (16:8 TRF Control): * Confirmed practice of 16:8 TRF (fasting window 16 hours or more per day) throughout the study period\[cite: 1\] * Not observing Ramadan dry fasting during the study period\[cite: 1\] Exclusion Criteria: * Established type 1 or type 2 diabetes (HbA1c 6.5% or higher or pharmacological antidiabetic therapy)\[cite: 1\] * Severe gastrointestinal, cardiovascular, hepatic, or renal disease (eGFR less than 60 mL/min/1.73m²)\[cite: 1\] * Active cancer or chemotherapy within five years\[cite: 1\] * Use of metformin, statins, or exogenous antioxidant supplements (vitamins C, E, NAC, CoQ10) within 30 days of screening\[cite: 1\] * Pregnancy, lactation, or planned conception during the study period\[cite: 1\] * Participation in another clinical study within three months\[cite: 1\] * Inability to provide written informed consent in Arabic or English\[cite: 1\]

Outcomes

Primary Outcomes

Between-arm difference in PINK1 and Parkin mitophagy gene expression

Relative expression levels of PINK1 and Parkin mRNA will be quantified via probe-based quantitative reverse transcription PCR (qRT-PCR) from isolated peripheral blood mononuclear cells (PBMCs). Normalization will be performed using the geometric mean of housekeeping genes GAPDH and B2M. Evaluation will focus on the between-arm contrast (Arm A vs. Arm B) of the change metric using relative quantification (2\^-ΔΔCt).

Time frame: Change from baseline (Day -3) to Day 30 of the fasting period

Between-arm difference in mitochondrial DNA copy number (mtCN)

Mitochondrial DNA copy number will be quantified by qPCR targeting the mitochondrial reference region MT-RNR1 (12S rRNA), normalized to the nuclear reference gene B2M. Relative mtCN is calculated using the formula: 2 × (Ct\_nuclear - Ct\_mtDNA). The primary evaluation is the between-arm difference in net change at Day 30 to test for a predicted U-shaped cellular trajectory